PATH-17. HYPERPROGRESSIVE DISEASE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMAS TREATED WITH IMMUNE CHECKPOINT INHIBITORS OR CYTOTOXIC THERAPIES

BACKGROUND: Hyperprogressive disease (HPD), defined as a ≥ 2-fold increase in tumor growth rate (TGR) compared to baseline following initiation of immune checkpoint inhibitors (ICI), has been described in solid tumors but is not well explored high grade gliomas (HGG). We investigated the rate of HPD...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Donovan, Laura, Gedailovich, Samuel, Joanta-Gomez, Adela, Lassman, Andrew, Iwamoto, Fabio
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Molecular Pathology and Classification - Adult and Pediatric
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847436/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.613
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki